PSCA (Prostate Stem Cell Antigen 2)

Finally, we designed a new synthetic co-stimulatory receptor that potentiates AP-1 activation resulting in improved in-vivo persistence. These results highlight fundamental biological differences between γδ and αβ T cells and support the development of cell type-specific receptor engineering strategies to maximize γδ CAR-T cell function and therapeutic benefit.

IDC-P possesses a distinct molecular and immunological profile. Understanding these molecular underpinnings is crucial for the development of personalized treatment strategies for histologically distinct prostate cancer subsets.

For example, genotypes at variants in the PSCA locus were perfectly predicted by urine PSCA levels and associated with PSCA expression and diseases of PSCA-expressing tissues, including bladder cancer and urinary tract infections, demonstrating potential clinical utility of urine protein levels. These findings are accessible through a convenient web application, and establish a comprehensive genetic framework for kidney protein handling to facilitate clinical and experimental investigations.

Additionally, this review aims to systematically summarize the relevant progress in this field. In conclusion, the findings provide a theoretical basis and clinical guidance for molecular-targeted therapy in PCa, thereby promoting further research and applications.

P1, N=21, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2026 --> Nov 2028 | Trial primary completion date: Nov 2026 --> Nov 2028

Druggability analyses nominated several potential drug targets for PCa, such as HSPB1, RRM2B, and PSCA. Our findings reveal novel risk loci and candidate protein biomarkers, providing new etiological insights and potential avenues for PCa early detection and therapy.

BsAbs are a promising therapeutic strategy for mCRPC, with potential to improve outcomes in this poorly treatable disease. Addressing challenges (toxicity, tumor microenvironment, response durability) via research and trials is key to unlocking their full potential. Future research should focus on optimizing constructs, exploring novel targets, and developing combination therapies to advance BsAbs in prostate cancer.

Finally, integrating previously published datasets with our data, we generate a prostate PDO single-cell atlas (PPScA), which captures a spectrum of cellular identities while revealing pathways altered in vitro. Our study provides methodological improvements for short-term culture and cellular biology insights.

C1 is mainly enriched in metabolism-related pathways, and C2 is mainly enriched in the activation of genome instability pathways, accompanied by more frequent mutations and higher Atezolizumab response...This study identified a promising platform for understanding heterogeneity of CAFs-based BLCA subtypes, providing novel insights into the intricate molecular mechanisms of BLCA. Potential target genes for each subtype provide a basis for diagnosis and screening of BLCA patients.

Several LY6/uPAR members have emerged as promising clinical targets, with translational strategies encompassing CAR-T cell therapies, antibody-drug conjugates, and lipid raft-modulating agents. This review presents a comprehensive overview of current knowledge, linking the structural, spatial, and functional characteristics of LY6/uPAR proteins to their relevance in health and disease, identifying key unresolved mechanistic questions, and underscoring emerging translational opportunities within the context of precision immunology.

We discovered that certain genetic changes offer protection against UBC, particularly in individuals exposed to tobacco smoke. Understanding these genetic factors could improve strategies for preventing and treating UBC.

To address these challenges, we further discuss various optimization strategies, including target selection, combination of immune checkpoint inhibitors or tumor microenvironment modulators, and optimization of CAR structural design and delivery methods. In the future, through the exploration of multi-dimensional optimization design and combination therapeutic regimen, it is expected to facilitate the broader application and clinical translation of CAR-T therapy in solid tumor treatment.